Abstract 1599P
Background
In PSMAfore (NCT04689828), [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolonged rPFS versus androgen receptor pathway inhibitor (ARPI) change in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). We now present the time to symptomatic skeletal events (SSE) and time to worsening (TTW) in health-related quality of life (HRQoL) and pain at the third interim analysis (data cutoff, 27 Feb 2024).
Methods
Eligible patients had mCRPC, were candidates for ARPI change after one progression on previous ARPI, and had ≥1 PSMA-positive and no exclusionary PSMA-negative metastatic lesions by [68Ga]Ga-PSMA-11 PET/CT. Patients were randomized 1:1 to open-label 177Lu-PSMA-617 (7.4 GBq q6w; 6 cycles) or ARPI change (abiraterone/enzalutamide). Patients with confirmed radiographic progression on ARPI change could cross over to 177Lu-PSMA-617. The primary endpoint was rPFS. Other endpoints included time to SSE and TTW in self-reported HRQoL (FACT-P, EQ-5D-5L; secondary) and pain (BPI-SF; exploratory).
Results
In total, 468 patients (234/arm) were randomized. Median duration of exposure was 8.4 months for 177Lu-PSMA-617 and 6.5 months for ARPI change. 177Lu-PSMA-617 prolonged time to SSE and fewer bone fractures were reported versus ARPI change (4 [1.7%] vs 13 [5.6%]) (Table). 177Lu-PSMA-617 prolonged TTW in FACT-P, EQ-5D-5L and BPI-SF versus ARPI change (Table). Incidences of grade ≥3 adverse events (AEs), serious AEs and AEs leading to discontinuation for 177Lu-PSMA-617 and ARPI change were 36% and 48%, 20% and 32%, and 5.7% and 5.2%, respectively. Table: 1599P
177Lu-PSMA-617 (n = 234) | ARPI change (n = 234) | HR (95% CI) | |
Time to SSE or death, months, median (95% CI) | NE (NE, NE) | 17.97 (14.26, NE) | 0.41 (0.26, 0.63) |
SSE, n (%) | 27 (11.5) | 63 (26.9) | – |
Pathological bone fracture | 4 (1.7) | 13 (5.6) | – |
Spinal cord compression | 6 (2.6) | 4 (1.7) | – |
Tumour-related orthopaedic surgical intervention | 1 (0.4) | 3 (1.3) | – |
Radiation therapy to relieve bone pain | 16 (6.8) | 43 (18.4) | – |
Death without SSE, n (%) | 4 (1.7) | 5 (2.1) | – |
TTW, months, median (95% CI) | |||
FACT-P total | 7.46 (6.08, 8.54) | 4.27 (3.45, 4.50) | 0.61 (0.50, 0.75) |
EQ-5D-5L utility score | 6.28 (4.70, 7.89) | 3.88 (3.25, 4.44) | 0.67 (0.54, 0.82) |
BPI-SF pain intensity | 5.13 (4.11, 6.14) | 3.65 (3.06, 4.34) | 0.73 (0.59, 0.88) |
DCO, 27 Feb 2024NE, not estimable
Conclusions
177Lu-PSMA-617 clinically meaningfully and significantly prolonged time to SSE and TTW in self-reported HRQoL and pain versus ARPI change in taxane-naive patients with PSMA-positive mCRPC.
Clinical trial identification
NCT04689828.
Editorial acknowledgement
Under direction of the authors, Sophie Adams, PhD, of Oxford PharmaGenesis, Oxford, UK provided medical writing support, which was funded by Novartis.
Legal entity responsible for the study
Novartis.
Funding
Novartis.
Disclosure
K. Fizazi: Financial Interests, Personal and Institutional, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Arvinas, CureVac, Macrogenics, Orion; Financial Interests, Personal, Advisory Board: Amgen, Astellas, AstraZeneca, Bayer, Clovis, Daiichi Sankyo, Janssen, MSD, Novartis, Pfizer, Sanofi. M.J. Morris: Financial Interests, Institutional, Research Grant: Bayer; Progenics; Corcept Therapeutics; Roche/Genentech; Janssen; Celgene; Novartis; Astellas Pharma; Financial Interests, Personal, Speaker, Consultant, Advisor: Lantheus Medical Imaging, AstraZeneca, Amgen, Daiichi Sankyo, Convergent Therapeutics, Pfizer, ITM Isotope Technologies Munich, Clarity Pharmaceuticals, Blue Earth Diagnostics, POINT Biopharma, Telix Pharmaceuticals, Progenics, and Z-Alpha; Financial Interests, Personal, Other, Support for attending meetings and/or travel: AstraZeneca, APCCC, and Memorial Sloan-Kettering Cancer Center; Financial Interests, Personal, Stocks/Shares: Doximity. N.D. Shore: Financial Interests, Personal, Advisory Board: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Cold Genesys, Dendreon, Exact Imaging, Genesis Care Us, Invitae, Janssen, MDxhealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Propella, Sanofi Genzyme, Speciality Networks, Tolmar, Urogen, Clarity, Lantheus, Lilly, Photocure, Telix, Photocure, Asieris, Alessa Therapeutics, Arquer, Fize medical, GConcology, Guardant, Ferring, Foundation Medicine, Immunitybio, Incyte, Minomic, NGM, Nonagen, Novartis, PlatformQ, Promaxo, Protara, Accord, Antev, Aura biosciences, Sumitomo; Financial Interests, Personal, Member of Board of Directors: Photocure, Alessa Theraputics; Financial Interests, Personal and Institutional, Local PI: AstraZeneca, Bayer, Aura, Exact Imaging, Janssen, Merck, Myovant, Novartis, Pfizer, Propella, Bristol Myers Squibb, Dendreon, Pfizer, Urogen; Financial Interests, Institutional, Local PI: alessa, GC oncology, FORMA therapeutics, Pacific edge, Point Biopharma, The MT group, Theralase, Verity, Astellas, Palette Life Sciences, Steba, Zenflow. K.N. Chi: Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Janssen, Point Biopharma, Roche; Financial Interests, Personal, Advisory Board: AstraZeneca, AstraZeneca, Janssen, Merck, Novartis, Pfizer, Point Biopharma, Roche, BMS; Financial Interests, Institutional, Steering Committee Member: AstraZeneca, Janssen, Novartis, Roche; Financial Interests, Institutional, Trial Chair: AstraZeneca, Arvinas, Janssen, Novartis; Financial Interests, Institutional, Local PI: Arvinas. M. Crosby: Financial Interests, Personal, Steering Committee Member: Novartis; Financial Interests, Personal, Other, Consulting fees: Lantheus; Financial Interests, Personal, Other, Patient Advocacy Support Pfizer Patient Advocacy Support: Pfizer; Financial Interests, Personal, Other, Patient Advocacy Support Pfizer Patient Advocacy Support Pfizer Patient Advocacy Support: Johnson & Johnson; Financial Interests, Personal, Other, Patient Advocacy Support Pfizer Patient Advocacy Support: Sumitomo; Financial Interests, Personal, Other, Patient Advocacy Support: Astellas, AstraZeneca, BlueEarth Diagnostics, Boston Scientific, Elekta, Macrogenitcs, Profound Medical, Telix, Tempus, Tolmar; Financial Interests, Personal and Institutional, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Telix; Financial Interests, Personal and Institutional, Advisory Board, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Profind Medical, Pfizer, Johnson & Johnson; Financial Interests, Personal, Advisory Board: Telix; Financial Interests, Personal and Institutional, Advisory Board: Society of Nuclear Medicine and Molecular Imagin; Financial Interests, Personal and Institutional, Steering Committee Member: American Urological Association. J.S. de Bono: Financial Interests, Personal, Advisory Board: Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi Sankyo, Eisai, Genentech Roche, Genmab, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals, Menarini Silicon Biosystems, ImCheck Therapeutics, Crescendo, MetaCurUm, Myricx, Nurix Therapeutics, Oncternal Therapeutics; Financial Interests, Institutional, Advisory Board: Harpoon, Dark Blue Therapeutics, Novartis, Takeda, Tango Therapeutics; Financial Interests, Institutional, Research Grant: Astellas, AstraZeneca, Bayer, Cellcentric, Daiichi Sankyo, Genentech Roche, Genmab, GSK, Harpoon, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Sanofi Aventis, Sierra Oncology, Taiho, Vertex Pharmaceuticals, Crescendo Biologics, Menarini Silicon Biosystems, Immunic Therapeutics, MetaCurUm, Myricx, Nurix Therapeutics, Oncternal Therapeutics; Financial Interests, Institutional, Local PI: Amgen; Non-Financial Interests, Principal Investigator: Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi Sankyo, Eisai, Genentech Roche, Genmab, GSK, Harpoon, Janssen, Menarini Silicon Biosystems, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals, Crescendo, ImCheck Therapeutics, Immunic Therapeutics; Non-Financial Interests, Institutional, Product Samples: Daiichi Sankyo, Bayer, Merck Serono, AstraZeneca, Harpoon, Pfizer, Sierra Oncology, Genentech/Roche, Sanofi Aventis, GSK. K. Herrmann: Financial Interests, Personal, Advisory Board: Bayer, Adacap/Novartis, Curium, Boston Scientific, GE Healthcare, AstraZeneca; Financial Interests, Personal, Invited Speaker: Sirtex, Siemens Healthineers, Monrol; Financial Interests, Personal, Other, Consultant: Amgen; Financial Interests, Personal, Other, DMSB: ymabs; Financial Interests, Personal, Advisory Board, Scientific Advisor: AdvanceCell; Financial Interests, Personal, Advisory Board, Advisor, Consultant: Janssen; Financial Interests, Personal, Advisory Board, Consultant: Eco1R, Fusion Pharmaceuticals, Genentech; Financial Interests, Personal, Member of Board of Directors: Sofie Biosciences, Pharma 15; Financial Interests, Personal, Ownership Interest: Sofie Biosciences; Financial Interests, Personal, Stocks/Shares: Aktis Oncology, AdvanCell, Convergent Therapeutics; Non-Financial Interests, Leadership Role, Chair Oncology&Theragnostics Committee: EANM. G. Roubaud: Financial Interests, Personal, Advisory Board: Janssen, Astellas, Bayer; Financial Interests, Institutional, Advisory Board: Pfizer, AstraZeneca; Financial Interests, Institutional, Invited Speaker: Novartis; Financial Interests, Institutional, Coordinating PI: Bayer. J. Nagarajah: Financial Interests, Personal and Institutional, Research Grant: Novartis, ABX; Financial Interests, Personal, Speaker, Consultant, Advisor: CURIUM, POINT Biopharma; Financial Interests, Personal and Institutional, Other, Payment of honoraria for lectures, presentations, speakers bureaus, manuscript writing, educational events: Bayer, AG, Pfizer. M.T. Fleming: Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis. D.E. Castellano Gauna: Financial Interests, Personal, Advisory Board: Pfizer, Roche, BMS, Janssen, Astellas, MSD, Ipsen, AstraZeneca, Novartis, GSK; Financial Interests, Institutional, Local PI: Pfizer, Roche, MSD, BMS, AstraZeneca, Janssen, Astellas, Ipsen, Exelisis, Eisai, Lilly, Bayer, GSK, Clovis, QED Therapeutics; Non-Financial Interests, Other, any: Associate Professor of Medical Oncology/Internal Medicine department; Non-Financial Interests, Personal, Other, Executive member: SOGUG (Spanish Oncology Genito-Urinary Group) Foundation; Non-Financial Interests, Personal, Training, Head of GU Alliance for Research and Development Consortium: GUARD Consortium; Other, any: Member of the Internal/local Pharmacy Commission at the Hospital Universitario 12 de Octubre. N. Carnahan: Financial Interests, Institutional, Full or part-time Employment: Novartis Pharmaceuticals. S. Ghebremariam: Financial Interests, Personal, Full or part-time Employment: Novartis. M. Hertelendi: Financial Interests, Personal, Full or part-time Employment: Novartis. O. Sartor: Financial Interests, Personal, Other, All support for the present manuscript: Novartis; Financial Interests, Institutional, Research Grant: Novartis, Amgen, Bayer, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, Tenebio; Financial Interests, Institutional, Royalties: AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: ARTBIO, AAA, AstraZeneca, Bayer, Blue Earth Diagnostics, Clarity Pharmaceuticals, Fusion, Isotope Technologies, Merck, Janssen, Myovant, Myriad, Noria Therapeutics, Novartis, NorthStar, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix; Financial Interests, Personal, Other, Support for attending meetings and travel: Lantheus, Novartis, NorthStar; Financial Interests, Personal, Advisory Board: AstraZeneca, Merck, Pfizer; Financial Interests, Personal, Stocks/Shares: ARTBIO, Ratio, Clarity Pharmaceuticals, Convergent, Fusion, Pfizer, Telix; Financial Interests, Personal, Stocks or ownership: Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
1553P - Access to EMA approved drugs in Europe, disparities across a border
Presenter: Orla Fitzpatrick
Session: Poster session 10
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10